Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...

The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting ...

Adaptive Biotechnologies' MRD segment continues to show strong growth, with a 36% increase in revenue and clonoSEQ test volumes. The immune medicine segment remains weak, with a 66% drop in revenue, ...

Adaptive Biotechnologies (ADPT) shares rallied 18% in the last trading session to close at $7.16. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer ...

Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock rose 4.3% in Monday premarket trading following the announcement of two non-exclusive agreements with Pfizer Inc (NYSE:PFE) that ...

Janney Montgomery Scott LLC lifted its stake in shares of Global X Adaptive US Factor ETF (NYSEARCA:AUSF – Free Report) by 165.8% in the 4th quarter, according to the company in its most recent 13F ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. The commercial-stage Adaptive booked $58.9 ...

The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. These 10 stocks could mint the next wave of ...